HK1079400A1 - Compounds for the treatment of metabolic disorders - Google Patents

Compounds for the treatment of metabolic disorders

Info

Publication number
HK1079400A1
HK1079400A1 HK05111437.3A HK05111437A HK1079400A1 HK 1079400 A1 HK1079400 A1 HK 1079400A1 HK 05111437 A HK05111437 A HK 05111437A HK 1079400 A1 HK1079400 A1 HK 1079400A1
Authority
HK
Hong Kong
Prior art keywords
compounds
treatment
metabolic disorders
metabolic
disorders
Prior art date
Application number
HK05111437.3A
Other languages
English (en)
Chinese (zh)
Inventor
Kirvin L Hodge
Albert Lee
Shalini Sharma
Borstel Reid W Von
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of HK1079400A1 publication Critical patent/HK1079400A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05111437.3A 2003-02-13 2005-12-13 Compounds for the treatment of metabolic disorders HK1079400A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44716803P 2003-02-13 2003-02-13
PCT/US2004/003718 WO2004073611A2 (en) 2003-02-13 2004-02-09 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
HK1079400A1 true HK1079400A1 (en) 2006-04-07

Family

ID=32908414

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111437.3A HK1079400A1 (en) 2003-02-13 2005-12-13 Compounds for the treatment of metabolic disorders

Country Status (19)

Country Link
US (3) US7615575B2 (ja)
EP (2) EP2266946A3 (ja)
JP (2) JP4697962B2 (ja)
KR (1) KR101106631B1 (ja)
CN (1) CN1750758B (ja)
AU (2) AU2004212905B2 (ja)
BR (1) BRPI0407506A (ja)
CA (1) CA2513092C (ja)
ES (1) ES2530235T3 (ja)
HK (1) HK1079400A1 (ja)
IL (1) IL169332A (ja)
MX (1) MXPA05008600A (ja)
NO (1) NO334606B1 (ja)
NZ (1) NZ542072A (ja)
PL (1) PL377712A1 (ja)
RU (2) RU2005128501A (ja)
UA (1) UA81013C2 (ja)
WO (1) WO2004073611A2 (ja)
ZA (1) ZA200504558B (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104987C2 (uk) * 2001-06-12 2014-04-10 Уеллстат Терепьютікс Корпорейшн Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
WO2004041165A2 (en) * 2002-11-01 2004-05-21 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2513092C (en) * 2003-02-13 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR101127390B1 (ko) 2003-04-15 2012-03-23 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
NZ543789A (en) * 2003-04-30 2008-03-28 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
ATE502631T1 (de) * 2003-08-20 2011-04-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
EP1868595B1 (en) * 2005-04-01 2012-01-11 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
EP1976377A4 (en) * 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
NZ569728A (en) * 2006-01-25 2010-11-26 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
WO2007087506A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1983972A4 (en) * 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
ATE530066T1 (de) * 2006-02-28 2011-11-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
EP2001461A4 (en) * 2006-03-31 2010-06-09 Wellstat Therapeutics Corp COMBINATION TREATMENT FOR METABOLISM DISEASES
EP2019673A4 (en) * 2006-05-18 2010-06-16 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
AU2007257854B2 (en) * 2006-06-09 2012-04-12 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MX2009001763A (es) * 2006-08-17 2009-02-25 Wellstat Therapeutics Corp Tratamiento combinado para trastornos metabolicos.
FR2917084B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
NZ602321A (en) 2008-03-13 2013-02-22 Wellstat Therapeutics Corp Compound and use for reducing uric acid comprising 2-(3-(2,6-Dimethylbenzyloxy)-4-methylphenyl)acetic acid
AU2013200226B2 (en) * 2008-03-13 2015-01-15 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
JP5806221B2 (ja) 2009-10-13 2015-11-10 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる３−置換化合物
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
CN102399148B (zh) * 2010-09-14 2014-03-05 中国科学院成都生物研究所 一类降血脂化合物及其制备方法和用途
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
AU2015330643B2 (en) * 2014-10-10 2020-05-14 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
EP3864001A1 (en) * 2018-10-11 2021-08-18 Basf As Romatic compounds and pharmaceutical uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2100341A (en) * 1934-11-24 1937-11-30 United Shoe Machinery Corp Shoe bottom coating machine
GB1393854A (en) * 1973-02-26 1975-05-14 Pfizer Benzoic acid compounds and pharmaceutical compositions containing them
US4067892A (en) * 1973-08-23 1978-01-10 Beecham Group Limited Substituted (4-carboxyphenoxy) phenyl alkane compounds
US3976673A (en) 1974-01-14 1976-08-24 Isf Spa 4-Cyclopropylmethyleneoxy-3-chlorophenylacetic acid and salts thereof
CS175831B1 (ja) 1974-12-17 1977-05-31
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
US4268442A (en) 1978-11-14 1981-05-19 Sagami Chemical Research Center Process for preparing aromatic acetic acid
AU576457B2 (en) 1984-02-14 1988-08-25 Hirai, Hidefumi Process for preparing p-substituted phenol derivatives
DE3884825D1 (de) 1987-02-16 1993-11-18 Konishiroku Photo Ind Entwickler für lichtempfindliche lithographische Druckplatte, gemeinschaftlich verarbeitungsfähig für den Negativ-Typ und den Positiv-Typ und Entwicklerzusammensetzung für lichtempfindliches Material.
JPH0770025B2 (ja) 1987-09-16 1995-07-31 富士通株式会社 薄膜磁気ヘッドの製造方法
US4923501A (en) 1987-11-04 1990-05-08 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives, processes for their production, and herbicidal method and compositions
DE3738406A1 (de) * 1987-11-12 1989-05-24 Henkel Kgaa Sebosuppressive topische zubereitungen
JPH01216961A (ja) 1988-02-25 1989-08-30 Takeda Chem Ind Ltd １２−リポキシゲネース阻害剤
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
US4897397A (en) 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents
JPH0348603A (ja) 1989-07-14 1991-03-01 Wakayama Pref Gov 抗菌防臭材料
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
JPH08501100A (ja) * 1992-09-09 1996-02-06 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 除草性ベンゼン化合物
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JPH06293700A (ja) 1993-04-08 1994-10-21 Nippon Soda Co Ltd ６−クロロサリチル酸の製造法
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206658A (ja) 1994-01-12 1995-08-08 Shiseido Co Ltd 尋常性座瘡治療剤
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JPH08119959A (ja) 1994-10-20 1996-05-14 Oyo Seikagaku Kenkyusho キサントン誘導体及びこれを有効成分とするモノアミン酸化酵素阻害剤
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
US5530157A (en) 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
FR2730731B1 (fr) 1995-02-20 1997-04-04 Rhone Poulenc Chimie Procede de carboxylation d'un ether aromatique
WO1996028423A1 (fr) 1995-03-15 1996-09-19 Sankyo Company, Limited Composes dipeptidiques de structure ahpba
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP0906273B1 (en) 1996-05-24 2002-10-16 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
WO1998003505A2 (en) 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
JPH1087489A (ja) 1996-09-13 1998-04-07 Sankyo Co Ltd Ａｈｐｂａ構造含有ジペプチド化合物を有効成分とする医薬
WO1998010763A1 (en) * 1996-09-13 1998-03-19 Merck & Co., Inc. Thrombin inhibitors
JP3981771B2 (ja) 1996-10-19 2007-09-26 株式会社クレハ ２−ベンジルオキシ−６−アルコキシ安息香酸誘導体、その製造方法及び、農園芸用殺菌剤
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
EP1015453A4 (en) 1997-09-09 2001-09-19 Merck & Co Inc TYPE 3- (IODOPHENOXYMETHYL) CARBAPENEM ANTIBACTERIALS
ID23991A (id) 1997-09-30 2000-06-14 Daiichi Seiyaku Co Turunan-turunan sulfonil
AU735737B2 (en) 1997-10-14 2001-07-12 Asahi Kasei Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
CN1305454A (zh) * 1998-04-20 2001-07-25 藤泽药品工业株式会社 作为cgmp－磷酸二酯酶抑制剂的邻氨基苯甲酸衍生物
JP4154773B2 (ja) 1998-11-13 2008-09-24 住友電気工業株式会社 単結晶製造方法および装置
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
AUPQ570100A0 (en) 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
US6632765B1 (en) 2000-06-23 2003-10-14 Chervon U.S.A. Inc. Catalyst regeneration via reduction with hydrogen
KR100771286B1 (ko) 2000-06-28 2007-10-29 암젠 인크 퀴놀리닐 및 벤조티아졸릴 ｐｐａｒ-감마 조절물질
EP1300142A4 (en) 2000-07-05 2004-05-19 Ajinomoto Kk HYPOGLYCEMIC COMPOUNDS
AR031126A1 (es) 2000-08-29 2003-09-10 Abbott Lab Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
UA104987C2 (uk) 2001-06-12 2014-04-10 Уеллстат Терепьютікс Корпорейшн Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
DE10135027A1 (de) 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
EP1477472B1 (en) * 2002-02-21 2009-01-14 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivative and use thereof
WO2004041165A2 (en) 2002-11-01 2004-05-21 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
DE10257785A1 (de) * 2002-12-11 2004-07-01 Bayer Healthcare Ag Isophthalsäurederivate
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
CA2513092C (en) * 2003-02-13 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4282345B2 (ja) 2003-03-12 2009-06-17 株式会社日立製作所 半導体集積回路装置
KR101127390B1 (ko) * 2003-04-15 2012-03-23 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
CN1777576A (zh) 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
NZ543789A (en) 2003-04-30 2008-03-28 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
WO2005016862A1 (en) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
ATE502631T1 (de) 2003-08-20 2011-04-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
EP1660428A1 (en) 2003-08-20 2006-05-31 Eli Lilly And Company Ppar modulators
US7541455B2 (en) * 2003-12-22 2009-06-02 Ventana Medical Systems, Inc. Microwave mediated synthesis of nucleic acid probes
EP1868595B1 (en) * 2005-04-01 2012-01-11 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
NZ569728A (en) * 2006-01-25 2010-11-26 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
WO2007087506A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1976377A4 (en) * 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1983972A4 (en) * 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2019673A4 (en) * 2006-05-18 2010-06-16 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER

Also Published As

Publication number Publication date
NO20053211D0 (no) 2005-06-30
EP2266946A3 (en) 2012-12-12
ZA200504558B (en) 2010-04-28
PL377712A1 (pl) 2006-02-06
US7615575B2 (en) 2009-11-10
WO2004073611A3 (en) 2004-11-25
JP2009242434A (ja) 2009-10-22
IL169332A0 (en) 2007-07-04
ES2530235T3 (es) 2015-02-27
NO20053211L (no) 2005-10-20
KR20050098924A (ko) 2005-10-12
KR101106631B1 (ko) 2012-01-20
EP1601251A2 (en) 2005-12-07
US20100087541A1 (en) 2010-04-08
BRPI0407506A (pt) 2006-02-14
AU2008229824A1 (en) 2008-10-30
NZ542072A (en) 2007-11-30
RU2521284C2 (ru) 2014-06-27
RU2005128501A (ru) 2006-04-27
JP4697962B2 (ja) 2011-06-08
UA81013C2 (en) 2007-11-26
AU2004212905B2 (en) 2008-10-09
EP2266946A2 (en) 2010-12-29
NO334606B1 (no) 2014-04-22
IL169332A (en) 2011-04-28
CN1750758B (zh) 2012-06-20
MXPA05008600A (es) 2005-11-04
WO2004073611A2 (en) 2004-09-02
US20080015254A1 (en) 2008-01-17
US7932290B2 (en) 2011-04-26
EP1601251B1 (en) 2014-11-12
AU2004212905A1 (en) 2004-09-02
EP1601251A4 (en) 2007-03-28
RU2008151414A (ru) 2010-06-27
CA2513092A1 (en) 2004-09-02
CA2513092C (en) 2011-11-01
CN1750758A (zh) 2006-03-22
US7605181B2 (en) 2009-10-20
JP2006517920A (ja) 2006-08-03
US20060247309A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
IL169332A0 (en) Compounds for the treatment of metabolic disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
HU0302451D0 (en) New compounds with therapeutic effect
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
EP1654260A4 (en) 6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
GB0323258D0 (en) Therapeutic compounds
EP1653952A4 (en) OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
GB0400802D0 (en) Compounds for the treatment of disease
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
ZA200606780B (en) Compounds for the treatment of diseases
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0315877D0 (en) Compounds for the treatment of disease
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190206